Phase 3 Trial of Libtayo® (cemiplimab) Monotherapy in Advanced Cervical Cancer Stopped Early for Positive Result on Overall Survival ...Middle East

TARRYTOWN, N.Y. and PARIS, March 15, 2021 /PRNewswire/ -- Libtayo is the first immunotherapy to demonstrate improved overall survival in patients with cervical cancer, reducing the risk of death by 31% compared to chemotherapy Trial enrolled patients with advanced cervical cancer...

Hence then, the article about phase 3 trial of libtayo cemiplimab monotherapy in advanced cervical cancer stopped early for positive result on overall survival was published today ( Monday 15/03/2021 - 09:30 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Phase 3 Trial of Libtayo® (cemiplimab) Monotherapy in Advanced Cervical Cancer Stopped Early for Positive Result on Overall Survival )

Also on site :

• Trump posts boastful Atlas-inspired Truth Social image of himself carrying the world on his shoulders
• Donald Trump Compares Young Photo of Himself to Teenage Barack Obama
• SoftBank’s CEO isn’t the only one with questions about Elon Musk’s orbital data center hype